Issue 9, 2020

Gd(iii)–Pt(iv) theranostic contrast agents for tandem MR imaging and chemotherapy

Abstract

Pt(IV) prodrugs have emerged as versatile therapeutics for addressing issues regarding off-target toxicity and the chemoresistance of classic Pt(II) drugs such as cisplatin and carboplatin. There is significant potential for Pt(IV) complexes to be used as theranostic agents, yet there are currently no reported examples of Gd(III)–Pt(IV) agents for simultaneous MR imaging and chemotherapy. Here we report the synthesis, characterization, and in vitro efficacy of two Gd(III)–Pt(IV) agents, GP1 and GP2. Both agents are water soluble and stable under extracellularly relevant conditions but are reduced under intracellular conditions. Both are cytotoxic in multiple cancer cell lines, cell permeable, and significantly enhance the T1-weighted MR contrast of multiple cell lines. Thus, GP1 and GP2 are promising agents for tandem MR imaging and chemotherapy and provide a versatile platform through which future Gd(III)–Pt(IV) agents can be developed.

Graphical abstract: Gd(iii)–Pt(iv) theranostic contrast agents for tandem MR imaging and chemotherapy

Supplementary files

Article information

Article type
Edge Article
Submitted
22 Nov 2019
Accepted
28 Jan 2020
First published
28 Jan 2020
This article is Open Access

All publication charges for this article have been paid for by the Royal Society of Chemistry
Creative Commons BY license

Chem. Sci., 2020,11, 2524-2530

Gd(III)–Pt(IV) theranostic contrast agents for tandem MR imaging and chemotherapy

C. J. Adams and T. J. Meade, Chem. Sci., 2020, 11, 2524 DOI: 10.1039/C9SC05937G

This article is licensed under a Creative Commons Attribution 3.0 Unported Licence. You can use material from this article in other publications without requesting further permissions from the RSC, provided that the correct acknowledgement is given.

Read more about how to correctly acknowledge RSC content.

Social activity

Spotlight

Advertisements